<unk>  injections were proposed over a century ago however the number performed remained relatively low until the mid 2000s. Until 2001,<unk>  injections were mainly used to treat end-ophthalmitis. The number of<unk>  injections stayed fairly constant, around 4,500 injections per year in the US. The number of injections tripled to 15,000 in 2002 when triamcinolone injections were first used to treat diabetic macular oedema. This use continued to drive an increase to 83,000 injections in 2004. In 2005 bevacizumab and ranibizumab<unk>  injections for the treatment of wet-AMD caused a rise in injections to 252,000. In 2008, over 1 million<unk>  injections were performed. This doubled to 2 million just 3 years later in 2011 when another anti-VEGF<unk>  injection aflibercept became available for the treatment of wet AMD.<unk>  injections hit an all-time high in 2016 reaching over 5.9 million injections in the US.
Intravitreal administration
Intravitreal injection
Intracameral injection
Intracerebroventricular injection
Subcutaneous injection
Subcutaneous infusion
Intraperitoneal injection
Intramuscular injection